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Evidence-based medicine (EBM) has become a hot topic in medical practice, education, and research.
However, a large number of senior doctors did not have an opportunity to learn EBM in medical schools.
Firstly, this article addresses the history of EBM and the principle of practicing EBM, i.e., asking, acquiring,
appraisal, application, and auditing. Secondly, this article also provides a brief introduction to evidence-
based dermatology and compares the introduction of clinical practice guidelines between Europe, the
UK, and the US. Finally, this article addresses the present condition and future perspective of evidence-
based dermatology in Taiwan.
Copyright  2012, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Evidence-based medicine (EBM) has become a hot topic in medical
practice, education, and research. However, a large number of
senior doctors did not have an opportunity to learn EBM in medical
schools. The idea of using the evidence for medical practice could
be traced back to the time of ancient Greece.1 However, it was not
until the postwar period that EBM began to appear in modern
medicine. Archibald L. (Archie) Cochrane (1909e1988), a British
clinical epidemiologist, was the ﬁrst to advocate the principle of
EBM. In his most celebrated book entitled “Effectiveness and Efﬁ-
ciency. Random Reﬂections on Health Services,”2 he proposed that
the health-care resources are always limited and should be “efﬁ-
ciently” utilized based on evidence to provide “effective” health
care to as many people as possible. The best evidence of the
effectiveness of interventions is from randomized controlled trials
(RCTs). The same principle applies not only to treatments, but also
to diagnostic tests and screening procedures.
Inspired by Archie Cochrane, the academic centers in the UK and
Canada, in particular the Universities of Oxford and York in England
and McMaster University in Ontario (Canada), established the
explicit systematic methods to obtain the “best evidence.” One oforial Hospital, Chiayi, 6, Sec
: þ886 5 362 1000x2754.
ichi@gmail.com.
iwanese Dermatological Associatiothe most important methods of acquiring the best evidence is
meta-analysis, i.e., using a statistical method to obtain a pooled
intervention effect estimate from independent RCTs of adequate
quality to minimize biases and random error. In 1904, Karl Pearson,
a British pioneer statistician, ﬁrst proposed to combine the results
of individual studies to minimize random errors.3 In 1920s, Ronald
Fisher, another renowned British statistician, developed a statistical
method of meta-analysis which is known as Fisher’s combined
probability test.4 Gene Glass, an American statistician, coined the
term “meta-analysis” and illustrated its use in 1976.
Sir Iain Chamlers, a pioneer in EBM, was the ﬁrst to employ
meta-analysis in clinical medicine successfully. In 1990, his group
based in Oxford published the most famous meta-analysis entitled
“The effects of corticosteroid administration before preterm
delivery: an overview of the evidence from controlled trials.”5 By
1989, there had been seven RCTs examining the effects of prenatal
administration of corticosteroid to women who were about to give
birth prematurely. However, none of the studies had adequate
power to conclude the effects of corticosteroid on infant mortality.
Sir Iain Chamlers conducted ameta-analysis and found that a short,
inexpensive course of corticosteroids given to these women could
prevent infant respiratory distress syndrome and reduce the odds
of the babies of these women dying from the complications of
immaturity by 30e50%.5 Because no relevant meta-analysis had
been published until 1989, most obstetricians did not realize that
this simple treatment was so effective. Tens of thousands of
premature babies might thus have died unnecessarily. This is justn. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1 Levels of evidence pyramid (for treatment beneﬁt).
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perform up-to-date systematic reviews (SRs) of RCTs of health care.
In the meantime, the McMaster University group led by
Professors Gordon Guyatt and David Sackett in Canada advocated
the EBM paradigm for medical practice and education. They ofﬁ-
cially announced the term “EBM” in their article published in 1992,
and deﬁned EBM as “the conscientious, explicit, and judicious use
of current best evidence in making clinical decisions about the care
of individual patients.”6
Practice of EBM
The whole idea of EBM is to use the best evidence to resolve clinical
uncertainty and to provide effective and efﬁcient health-care
interventions to promote the well-being of people. The complete
practice of EBM is composed of ﬁve basic steps (also known as
“5As”): (1) asking a clinical question, (2) acquiring the evidence by
a thorough search of the literature, (3) appraisal of the validity and
relevance of the retrieved articles, (4) applying the evidence to
clinical practice, and (5) auditing the performance of the practice.
(1) Asking a clinical question
In the ﬁrst step, clinicians encounter a scenario where decisions
have to be made to resolve a clinical problem, and become aware of
the limitation in knowledge. EBM formulates a focused clinical
question using the PICO structure of four elements: patient/pop-
ulation/problem (P), intervention (I), comparator (C), and outcome
(O). For example, a dermatologist was frequently asked about the
efﬁcacy of probiotic intake in atopic eczema by parents of affected
children. This dermatologist then organized this uncertainty into
a structured clinical question: “Are probiotics useful in treating
atopic eczema?” Thus, the four elements of the question are atopic
eczema as P, probiotics as I, placebo or no interventions or another
intervention as C, and efﬁcacy as O. It is important to identify the
four elements, because in this process one will have a clear
understanding of the speciﬁc question she/he is asking and these
elements will be used to design a search strategy for ﬁnding rele-
vant evidence.
(2) Acquiring the evidence
In the second step, the evidence is acquired by a thorough
search of the literature. This step is one of the major differences
between EBM and traditional narrative review. Narrative review
articles rely on the review authors to collect evidence and therefore
may be biased due to authors’ preference, access to bibliographies,
and conﬂicts of interest. EBM uses a transparent systematic way of
collecting evidence by a rigorous search of bibliographic databases.
The electronic databases frequently used include MEDLINE/
PubMed, EMBASE, the Cochrane Central Register of Controlled
Trials (CENTRAL) in The Cochrane Library, and the Latin American
and Caribbean Health Science Information (LILACS) database. The
Airiti Library is a Taiwanese bibliographic databasewhich should be
searched for obtaining relevant local evidence. As the number of
medical publications from China has been increasing rapidly over
the past few years, Chinese bibliographic databases may be
searched as well. However, there is a concern for the quality of
Chinese studies which the readers shall pay attention to.7
Trials with signiﬁcant statistical results are often accepted early
and easily for publication than those with nonsigniﬁcant results.8
This “publication bias” leads us to ﬁnd positive studies more
easily than negative studies. Therefore, the International
Committee of Medical Journal Editors announced in 2004 that for
a clinical trial to be considered for publication in one of its journals,the trial must be registered by September 2005 in a public clinical
trials register.9 The mandatory registration of trials before
commencement keeps a record of all clinical trials irrespective of
whether the results of a study are published or not. The Cochrane
Collaboration encourages its authors to search trial registers and to
correspond with trialists and/or pharmaceutical companies for
unpublished data in order to minimize publication bias.10
A comprehensive search of the electronic databases needs
a properly designed search strategy. This search strategy is usually
a Boolean combination of (“P” AND “I” AND “O”) or just (“P” AND
“I”), the aforementioned elements of the clinical question proposed.
Medical subject headings (MeSH) and free text words are often
used to increase the sensitivity of the search strategy. To design
a proper search strategy, balancing sensitivity and speciﬁcity needs
frequent practice (trial and error) and the learning curve is some-
times quite long. Inexperienced people may seek the assistance of
experienced systematic reviewers or information specialists.
(3) Appraisal of the evidence
Mainly based on study design, the Oxford Centre for EBM
proposed a classiﬁcation of levels of evidence (Figure 1).11,12 We
usually only adopt the evidence from SRs (Level 1) and RCTs (Level
2), and use the evidence from nonrandomized studies only when
no evidence of higher level is available.
After identifying relevant RCTs from the search results, the
individual quality of the studies has to be appraised. This critical
appraisal usually covers three aspects of the evidence: validity,
clinical relevance, and applicability. There are a number of critical
appraisal tools, with the tools developed by the UK Critical
Appraisal Skills Programme and Oxford Centre for EBM being the
most widely used ones in Taiwan.13,14 With regard to the risk of
bias, the Cochrane Collaboration has its own tool.15 The Cochrane
tool is the benchmark for assessing the risk of bias in RCTs, but it
only examines the validity and is not an easy-to-use tool for inex-
perienced people.
The dermatologist who proposes the aforementioned clinical
question has searched PubMed and found a relevant German RCT
out of 116 citations.16 Before adopting the study results for clinical
practice, a critical appraisal of the RCT needs to be done. I have
devised a critical appraisal sheet which can easily be used by
beginners and show the results of critical appraisal for this RCT in
Table 1. The evidence from this RCT was judged valid and revealed
that probiotics were ineffective in treating atopic eczema.
Table 1 Critical appraisal tool.
Appraisal Comments
Validity
(1) Was the assignment of patients to interventions randomized? Low risk of bias The participants were randomized to either the probiotic
or placebo group
(2) Was the allocation concealed? Unclear risk of bias No relevant description
(3) Were the groups similar at the start of the trial? Low risk of bias No signiﬁcant differences in baseline characteristics
and severity between the probiotic and placebo groups
(4) Was follow-up of patients sufﬁciently long and complete? Low risk of bias The treatment duration of the study was 12 weeks,
which was longer than those of previous studies
(5) Were all patients analyzed in the groups to which they
were randomized? (Intention-to-treat analysis)
Unclear risk of bias 102 out of the 106 enrolled subjects completed the trials,
with 4 being withdrawn from the trial due to protocol violation.
The data on the 102 participants were used for analysis.
Therefore, this study used available case analysis, instead
of intention-to-treat analysis
(6) Were measures objective or were the patients and
clinicians kept “blind” to which intervention was being received?
Low risk of bias Double-blind study design
(7) Were groups treated equally, apart from the experimental therapy Low risk of bias The participants in both groups were encouraged to apply
ordinary skin care and avoid allergens or irritants
Clinical relevance
(1) What is the magnitude of the intervention effect? No therapeutic effects
of probiotics
No signiﬁcant effects of probiotics on symptom load,
SCORAD index score, etc. The primary outcome parameter e the
mean reduction of the symptom load score (SLS) at the end of
week 12 e was 4.94 (SD 14.73; median 7.1, range 0.92e8.96) in
the probiotics group and 8.53 (SD 10.90; median 9.5, range
5.37e11.70) in the control group (P ¼ 0.144)
(2) How precise is the estimate of the intervention effect? Low precision 54 vs. 48 participants
Applicability
(1) Is our patient so different from those in the
trial that its results cannot apply?
No
(2) Is the intervention feasible in our setting? Yes
(3) What are our patient’s potential beneﬁts
and harms from the therapy?
Beneﬁts: No signiﬁcant
potential beneﬁts
Harms: No signiﬁcant
potential harms
(4) What are our patient’s values and expectations for both
the outcome we are trying to prevent
and the intervention we are offering?
Patient’s values: his atopic
eczema is annoying and
needs to be treated
Patient’s expectation:
wish for an effective
and safe treatment
Plan
Steps 1-3 of EBM, 
i.e. asking, 
acquiring, and 
appraisal 
Do
Step 4 of EBM, 
application 
Act
If pilot works, 
spread
horizontally,
otherwise replans 
Check
Step 5 of EBM, 
auditing
Figure 2 The relationship between planedoeactecheck cycle and evidence-based
medicine (EBM).
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After having the evidence at hand, the fourth step is to judge the
applicability of the evidence to speciﬁc patients. The evidence is
from a trial on a group of German children and thus may have
limited external validity. However, there is no convincing reason
indicating a different response of Taiwanese children to probiotics.
The aforementioned dermatologist uses his expertise to judge that
this evidence could be applied to his patients. He decides to inform
parents of affected children that the current evidence found no
efﬁcacy of probiotics in treating established atopic eczema and
there is no scientiﬁc ground for the children to take probiotics.
(5) Auditing the performance of the practice
The ﬁfth step of EBM is to audit and get feedback of the clinical
practice to improve performance. This step is similar to the “check
phase” in the planedoeactecheck cycle that is frequently used in
quality improvement. After agreeing on an act to be implemented,
efﬁcacy and/or quality outcomes should be introduced and used for
evaluating the performance of the evidence-based practice. If the
practice works, standard operating protocols (SOPs) and/or guide-
lines shall be developed and horizontally spread to colleagues to
improve the quality of the health-care system. If the practice does
not work, a recheck of the barriers to implementation and an
analysis of the reasons for failure should be done. Modiﬁcation of
the practice should be done and a new planedoeactecheck cycle
follows (Figure 2).
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and explicit method, SR, to acquire, appraise, and synthesize the
best evidence on a clinical question, with the aim of reducing biases
and random errors. SRs are transparent and reproducible, which
are in contrast to traditional narrative reviews. Narrative reviews
are often written by prestigious experts in a speciﬁc ﬁeld. Narrative
reviews frequently cover a broad topic and serve as articles for
continuing medical education. However, they are based on authors’
knowledge and preference of available data. The process of
preparing narrative reviews is nontransparent and subjective. The
results of narrative reviews are thus irreproducible and subjective
to biases. Therefore, SRs are more methodologically rigorous than
narrative reviews.
In SRs, meta-analyses may be used to obtain a statistically
pooled effect estimate. Cochrane reviews are conducted under the
guidance and surveillance of Cochrane Review Groups, and thus
have a higher quality than non-Cochrane SRs.17 Cochrane reviews
are published in the Cochrane Database of Systematic Reviews. To
overcome the language barrier in using the best evidence in health
care in Taiwan, the National Health Research Institute has prepared
Mandarin abstracts of over 3,500 Cochrane reviews and provides
them at a Mandarin website: http://clc.nhri.org.tw/admin/
clcmain1.aspx.18
Having illustrated the principle, EBM, however, is not “cook-
book”medicine. It should be kept in mind that evidence is the base,
not the host, for making decisions. It requires the integration of the
best research evidence with clinicians’ expertise, patients’ unique
values, and circumstances for making clinical decisions (Figure 3).
Evidence-based dermatology
Evidence-based dermatology is the utilization of EBM in derma-
tology. The Cochrane Skin Group (CSG) is an international organi-
zation which was established in 1997 with the aim of preparing,
maintaining, and promoting the accessibility of Cochrane reviews
of the effects of health care interventions in dermatology.19 To date,
the CSG has over 100 Cochrane reviews covering various topics,
ranging from efﬁcacy of interventions to the safety of drugs.20,21
Interested readers may ﬁnd further details from the book auth-
ored by the CSG Editors.22
Evidence-based clinical practice guidelines (CPGs) can assist
busy clinicians in making clinical decisions based on the best
evidence and skipping the tedious process of acquiring and
appraisal of evidence. CPGs can also promote efﬁcient use of limited
health-care resources. In countries where patients are mainly cared
for by general practitioners and are transferred to specialists only
when necessary, CPGs are very important as they provide generalFigure 3 Evidence-based medicine is not cookbook medicine but requires the inte-
gration of the best research evidence with clinicians’ expertise, patients’ unique values,
and circumstances for making clinical decisions.practitioners with a useful guide in effectively and efﬁciently
delivering health care services. However, clinicians should be aware
that the CPGs reﬂect the best evidence available at the time they are
prepared. Caution should be exercised in interpreting the data; the
results of future studiesmay require alteration of the conclusions or
recommendations in the CPGs. Adherence to CPGs does not guar-
antee treatment success in every clinical situations (remembering
that EBM is not cookbook medicine but instead needs to integrate
evidence, expertise, and patient’s expectation and circumstances).
It may be necessary or even desirable to depart from the CPGs in
special circumstances. Therefore, CPGs shall not be interpreted as
standards of care and thus deviating from them should not be
necessarily deemed negligent in litigation.
The European Dermatology Forum was founded in 1997 by
a group of leading European Professors of Dermatology. The Euro-
pean Dermatology Forum has an explicit SOP for developing CPGs
and has published over 30 CPGs. The British Association of
Dermatologists (BAD) also has an SOP for developing CPGs which is
accredited by the NHS Evidence.23 The BAD has a Therapy and
Guidelines Subcommittee and has published 30 CPGs. Compared
with the BAD, the American Academy of Dermatology (AAD) has
a slower pace in developing CPGs. The AAD now has a Clinical
Guidelines Committee, but only has nine published CPGs (with six
on psoriatic diseases).
Rise of evidence-based dermatology in Taiwan
Researchers in Taiwan have joined the CSG since 2006 and have
published two Cochrane reviews and are preparing two other
reviews.20,21,24 Dr Ching-Chi Chi (Chang Gung Memorial Hospital,
Chiayi) started to serve as a CSG Editor since 2011. Other derma-
tologists have published a few non-Cochrane SRs.25e27
Dr Yu-Hung Wu (Mackay Memorial Hospital, Taipei) has
developed the Mandarin version of the Fresno test for evaluating
EBM education. Drs Wu and Chi are currently Directors of the
Centers for EBM in their hospitals, respectively. The teams orga-
nized by them havewon a number of goldmedals in the yearly EBM
Application Contest of the Healthcare Quality Improvement
Campaign held by the Taiwan Joint Commission on Hospital
Accreditation. Dr Yao-Kun Chiu was the Director of the Centers for
EBM in Mennonite Christian Hospital, Hualien. All the three
dermatologists are devoted to EBM education.
Future perspectives
In Taiwan, EBM has been introduced in medical education for years,
and is now an essential component of postgraduate year training.
Compared with the older generation, the majority of young
dermatologists have received EBM education in medical schools.
This year, the written test for Taiwan’s Board of Dermatology
Specialist for the ﬁrst time contained a question on the levels of
evidence. As more young dermatologists are aware of and involved
in EBM, it is expected that the output of evidence will increase and
dermatologistswill havemore evidence support in decisionmaking.
Compared with the BAD and AAD, the Taiwanese Dermato-
logical Association is slow in developing CPGs and does not have
a guideline committee yet. However, as the ﬁnancial constraints of
Taiwan’s National Health Insurance have become tighter over the
past few years, the governing body has introduced evidence-
based health technology assessment in policy making, such as
the reimbursement approval and criteria of ustekinumab.28 There
has been a call for the Taiwan Government to establish an orga-
nization like the UK National Institute for Health and Clinical
Excellence to meet the increasing need for health technology
assessment. Dermatologists in Taiwan have been practicing based
C.-C. Chi / Dermatologica Sinica 31 (2013) 2e66on evidence to a certain degree. Undoubtedly, as other clinicians,
dermatologists will be directed to a more evidence-based practice
in the future.
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